Recognizing and Treating HFpEF: How Helpful Are MRAs, ARNi and SGLT2 Inhibitors for Treating Patients? What Have We Learned From The PARADIGM and PARAGON Trials?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

Confirm Password

About Us
Team
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Recognizing and Treating HFpEF: How Helpful Are MRAs, ARNi and SGLT2 Inhibitors for Treating Patients? What Have We Learned From The PARADIGM and PARAGON Trials?

By San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians FEATURING Barry Greenberg

February 5, 2021

0 Comments

2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Rev…

Feat. J. Butler

Considerations for Initiating a SGLT2 Inhibitor in Heart Failure Pat…

Feat. J. Butler

Primer on Diabetes Management

Feat. S. Inzucchi

18:43

ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

Feat. R. DeFronzo

26:01

Cardiology Fiesta 2017

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Feat. R. DeFronzo

11:37

ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich

13:07

Michelle Kittleson

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

27:24

Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Feat. L. Sloan

17:44

Rita Jermyn

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

19:30

ACC 2022 Conference Coverage

Hot Topics in Heart Failure ACC.22

Feat. N. Ibrahim

38:58

MUSC Cardiology

Inotropic Treatment for HFpEF? An Idea So Crazy It Just Might Be Rig…

Feat. S. Litwin

21:36

NYU Langone

Emerging Therapies in Cardiac Amyloidosis

Feat. M. Hanna

44:29

Houston Methodist DeBakey Heart and Vascular Center

Pathobiology, Clinical Relevance and the Future of Myocardial Recove…

Feat. A. Bhimaraj

10:02

Emory Diabetes Education Training Academy

Insulin Treatment in Patients with Type 2 Diabetes: When to Use Comb…

Feat. G. Umpierrez

13:42

George Bakris

Current Status of Prevention and Treatment of Diabetic Nephropathy

15:02

American College of Cardiology

ESC Congress 2022: DANCAVAS, REVIVED-BCIS2, ADVOR, ALL-HEART, and DE…

Feat. D. Bhatt, P. Gabriel Steg, P. Kohli

11:50

American Heart & Vascular Institute

New Medications for Heart Failure: SGLT2 Inhibitors and Vericiguat. …

Feat. M. Kittleson

12:23

American Heart & Vascular Institute

SGLT2 Inhibitors for HF: Is this Therapy Helpful for Reducing the Ho…

Feat. M. Tipton

22:38

Scripps Health

Clinical Presentation of Amyloidosis: Who to Suspect? - a 2022 Update

Feat. R. Mohan

14:44

26th Annual San Diego Heart Failure Symposium

Broadening Indications for the Use of Angiotensin Receptor Neprilysi…

Feat. C. Yancy

24:19

University of Virginia School of Medicine and School of Nursing

GLP1-Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: How …

Feat. E. Barrett

15:25

Javed Butler

Login

Login

Join VuMedi

Recognizing and Treating HFpEF: How Helpful Are MRAs, ARNi and SGLT2 Inhibitors for Treating Patients? What Have We Learned From The PARADIGM and PARAGON Trials?

Related Content